Jin Wang

Wang

Jin Wang, Ph.D.

Director

(713) 798-6875

Positions

Director
Center for NextGen Therapeutics
Baylor College of Medicine
Houston, Texas, United States
Michael E. DeBakey, M.D., Professor in Pharmacology
Biochemistry and Molecular Pharmacology
Baylor College of Medicine
Houston, Texas, United States
Professor
Molecular and Cellular Biology
Baylor College of Medicine
Houston, Texas, United States
Member
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas, United States

Addresses

1 Baylor Plaza (Office)
Room: Alkek N520.05
Houston, TX, 77030
United States

Education

BS from Peking University
07/2003 - Beijing, China
Chemistry
PhD from The Ohio State University
12/2007 - Columbus, Ohio, United States
Organic Chemistry
Postdoctoral Training at University of North Carolina at Chapel Hill
05/2011 - Chapel Hill, North Carolina, United States
Drug Delivery and Nanomedicine

Honors & Awards

Michael E. DeBakey, M.D., Professorship in Pharmacology
Baylor College of Medicine (06/2021)
Teaching Award - Outstanding Lecturer
Baylor College of Medicine Graduate School (12/2020)
Teaching Award - Chemical Biology as the Best Course in the CPSB Program
Baylor College of Medicine Graduate School (12/2020)
Distinguished Faculty Award
Chinese American Chemistry & Chemical Biology Professors Association (CAPA) (12/2020)
CPRIT Scholar in Cancer Research
Cancer Prevention and Research Institute of Texas (CPRIT) (07/2011)

Professional Interests

  • Chemical Biology
  • Sensors and Probes
  • Small Molecule Drug Discovery
  • Proteolysis-Targeting Chimeras (PROTACs), Targeted Protein Degradation (TPD)
  • Antibody Drug Conjugates (ADCs)
  • Proteomics and Chemoproteomics
  • Cancer Immunotherapies
  • Auto-inflammatory and auto-immune diseases
  • Neurodegenerative diseases, such as Alzheimer's disease (AD)
  • Metabolic diseases, such as obesity

Professional Statement

At Baylor College of Medicine (BCM), my research harnesses the power of chemistry to address fundamental questions in biology and drive therapeutic innovation. We function as a highly integrated academic drug discovery unit, mirroring many capabilities of a biotech setting. Our expertise covers the spectrum from target identification and validation to preclinical testing, including artificial intelligence (AI) and physics-based computational modeling (folding, docking, MD simulations), medicinal chemistry, structural biology, biochemical and cell-based assay development, in-house DMPK profiling, and evaluation in animal models. This comprehensive approach allows us to rationally design diverse therapeutic modalities like small molecule inhibitors, protein degraders (PROTACs, molecular glues), and antibody-drug conjugates, as well as novel chemical biology tools. Notable achievements include developing the widely adopted quantitative GSH fluorescent probe, pioneering SI-2 inhibitors against the challenging SRC-3 oncoprotein, and creating a novel brain-penetrant sEH inhibitor for Alzheimer's disease. Currently, we are intensely focused on advancing targeted protein degradation strategies and employing chemoproteomics to identify novel covalent inhibitors, ultimately aiming to translate our discoveries into improved human health outcomes.

Websites

Center for NextGen Therapeutics
Wang Research Group
Dr. Wang's Research
VIICTR Research Database

Selected Publications

Funding

Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
#1R01CA268518-01
(06/01/2022 - 05/31/2027)
Grant funding from NIH/NCI
RIP PROTACs as a Novel Immunotherapy Sensitizer to Treat Colorectal Cancer
#RP220480
(03/01/2022 - 02/28/2025)
Grant funding from CPRIT
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease
#U01AG068031
(09/15/2020 - 05/31/2025)
Grant funding from NIH/NIA
Reversible Covalent BTK Degraders As the Next Generation Targeted Therapy To Treat B-Cell Malignancies
#R01CA250503
(07/01/2020 - 06/30/2025)
Grant funding from NIH/NCI
TARGETING A LIPID-MEDIATED PRO-LONGEVITY PATHWAY AS ALZHEIMER'S THERAPY
#RF1AG062257
(09/15/2018 - 06/30/2023)
Grant funding from NIH/NIA
Drugging the Undruggable Coactivators using Small Molecule Inhibitors
#R01CA207701
(03/15/2017 - 02/28/2022)
Grant funding from NIH/NCI
Real-Time Quantitative Imaging of Intracellular Biothiol Dynamics
#R01GM115622
(09/22/2015 - 07/31/2021)
Grant funding from NIH/NIGMS
Engineering Antibody Drug Conjugates to Target P53-Defective Triple Negative Breast Cancer
#R21CA213535
(06/13/2017 - 05/31/2019)
Grant funding from NIH/NCI

Intellectual Property

Probes for Quantitative Imaging of Thiols in Various Environments
Product Patent (Pending)
Co Inventors: Xiqian Jiang; Jianwei Chen
Multi-arm biodegradable polymers for nucleic acid delivery
Product Patent (Approved)
Co Inventors: Fude Feng
Small molecule regulators of steroid receptor coactivators and methods of use thereof
Product Patent (Approved)
Co Inventors: Bert W. O’Malley, David M. Lonard, Jianming Xu, and Jianwei Chen
Small Molecule Proteolysis-Targeting Chimeras and Methods of Use Thereof
Product Patent (Pending)
Co Inventors: Jin Wang, Wen-Hao Guo, Xiaoli Qi, Michael Wang, Krystle Nomie, and Yang Yu
Novel Soluble Epoxide Hydrolase Inhibitors and Method of Use Thereof
Product Patent (Pending)
Co Inventors: Jin Wang, Hui Zheng, Lisheng Deng, and Anamitra Ghosh

Log In to edit your profile